Roche

News

BMS' subcutaneous Opdivo clears first phase 3 trial

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati

News

Roche ducks out of AC Immune Alzheimer's antibody alliance

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibo

News

Sandoz makes its first post-spinout acquisition

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in

News

Roche bags EU okay for subcutaneous Tecentriq

Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.

News

Roche antibiotic tackles serious drug-resistant pathogen

Scientists at Roche and Harvard University have discovered an entirely new class of antibiotic that can kill a highly drug-resistant ‘superbug’ with a mortality rate that can be upwar

News

Roche bolsters diagnostics with $295m LumiraDx deal

A flurry of mergers and acquisitions in the pharma space at the end of 2023 ended with a $295 million deal by Roche to buy a point-of-care diagnostics platform from Lumira

BMS' subcutaneous Opdivo clears first phase 3 trial

Roche ducks out of AC Immune Alzheimer's antibody alliance

Sandoz makes its first post-spinout acquisition

Roche bags EU okay for subcutaneous Tecentriq

Roche antibiotic tackles serious drug-resistant pathogen

Roche bolsters diagnostics with $295m LumiraDx deal

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Roche

Editor's Picks